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A BSTRACT
Quinolinol-based com pounds are a prom ising starting point for discovery o f effective inhibitors
o f the clostridial neurotoxin, botulinum neurotoxin type A light chain (BoNT/A LC). Insights
into the m echanism o f inhibition by quinolinol com pounds facilitate interpretation o f docking
data and inhibitor optim ization. In this study, a fluorogenic substrate o f BoNT/A, SN APtide, was
used to study the m echanism by w hich two new quinolinol com pounds, M SU58 and M SU 84,
w ith IC50 values o f 3.3 pM and 5.8 pM , respectively, inhibit BoN T/A LC. Kinetic studies and
m odel discrim ination analysis showed both com pounds to be com petitive inhibitors o f BoN T/A
LC w ith inhibition constants (Kj) 3.2 pM and 6.2 pM for M SU58 and M SU84, respectively. The
kinetic rate constant for substrate and inhibitor binding and release were also determ ined. These
data indicate that the inhibitors bind in the BoN T/A LC active site and that inhibitor binding is
m utually exclusive w ith the binding o f the substrate. This is the first study to report the
com petitive inhibition o f BoN T/A LC by quinolinol compounds. These data help define the
inhibitor binding pocket and, along w ith structure activity relationship studies, provide
im m ediate direction for further com pound synthesis.
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CH A PTER 1: INTRODU CTIO N
Botulinum neurotoxins (BoNTs) cause botulism , a deadly condition characterized by
flaccid paralysis. They have been categorized as Category A biow arfare agents by the
Centers o f D isease Control and Prevention f 1'2]. W hile w orldw ide there are only about
1000 cases reported yearly [3‘4], due to B oN T ’s potency and potential ease o f production
for bioterrorism activity, inhibitors are needed for the clinic [4'9]. Current therapy for
exposure to the toxin relies on inhibitory antibodies, which have several lim itations
including a lim ited supply o f the antitoxin, unknow n long term effects, and a short
application w indow (approxim ately 24 hours post exposure) [4'5>10]. Challenges in BoNT
inhibitor discovery include the large peptide substrate-enzym e interface, w hich m akes it
m ore difficult to define a site where an inhibitor m ay bind, and conform ational flexibility
o f BoNT [4’ H]. Quinolinol com pounds have been explored as BoNT inhibitors and
optim ization efforts can be aided by a deeper understanding o f the m echanism by which
com pounds inhibit BoNT activity.
BoNTs are produced by the anaerobic bacterium Clostridium botulinum and are
endoproteases that cause flaccid neurom uscular paralysis by blocking acetylcholine
release at the neurom uscular junction. BoNTs are secreted as holotoxins, consisting o f a
-1 0 0 kD heavy chain (HC) and a - 5 0 kD light chain (LC), linked by a disulfide bond [12~
14] (Figure 1). The LC is a zinc-dependent m etalloprotease while the HC facilitates the
targeting and internalization o f LC into cells [14]. There are seven antigenically distinct
serotypes o f BoNTs labelled A-G; serotype A is the m ost potent and m ost prevalent toxin
in hum ans [10,15]. W hen BoNT enters the bloodstream , the holotoxin is transported to the
neurotransm itter junction and enters the presynaptic neuron. The LC is liberated

1

intracellularly and cleaves soluble N -ethylm aleim ide-sensitive fusion attachm ent protein
receptor (SNARE) peptides and prevents acetylcholine release into the neurom uscular
junction, resulting in neurom uscular paralysis (botulism ) [10]. Intoxication w ith
botulinum toxins m ay occur naturally through ingestion o f contam inated food (foodbom e
botulism ), through w ounds contam inated with clostridia, or by deliberate introduction
through injection or inhalation [7].

FIGURE 1: Crystal structure of BoNT/A showing the 100 kD HC (green), 50 kD LC (blue,
cyan), the receptor binding domain (yellow, red orange) and the catalytic zinc (dark grey). The
crystal structure was obtained from the Protein Data Bank (PDB # 3BTA) and modified with
Chimera (UCSF, San Francisco, CA).
The natural substrate o f BoNT/A is a large 25 kD a peptide (SNAP-25, am ino acid
residues 1-206) [ l5' 16]. Studies have shown that although the presence o f the entire length
o f the natural substrate enhances substrate recognition and specificity, only the amino
acid residues 197-202 are in direct contact with the catalytic site o f BoN T/A LC.
Catalytic cleavage occurs at the scissile bond betw een residues 197 and 198 [2> l6]. Crystal
structures o f truncated substrate analogs (aa residues 197-202) bound to BoN T/A LC
2

(PDB ID # 3DDA, 3DDB) revealed m ultiple potential sub-binding sites (subsites) in the
active site [2]. The crystal structure # 3DDA shows that the carbonyl oxygen and N term inal N H 2 o f G ln l9 7 o f the substrate chelate the catalytic zinc in the BoN T/A LC
active site. The 8-hydroxyquinoline (quinolinol m oiety) was suggested to form a close
interaction with the zinc cation to exclude any w ater present at the active site [9’ I7],
possibly m im icking the interaction betw een Gin 197 o f the substrate w ith the catalytic
zinc. The salt bridge form ed betw een the guanidinium o f A rg l9 8 sidechain and Asp370
sidechain (BoNT/A LC residue) also appears to be crucial for catalytic activity [2].
Burnett and coworkers suggested that there are two binding subsites (1 and 2) in the
catalytic region o f BoN T/A LC that are im portant for the proper binding and orientation
o f small m olecule inhibitors. The hydrophobic pocket o f subsite 1 is occupied by the
arom atic sidechains P h el6 2 , P h el7 7 and P hel93 and the m ethyl side chain o f Thr219.
Hydrophobic interactions with a m ethyl substituent o f a chemical com pound are typical
interactions found in this site [9]. Subsite 2 is a deep pocket and consists o f M etl64,
T h rl7 5 , Arg230, Pro238 and His226, which is required for catalysis. Several polar
residues, Glu55, G ln l6 1 , G lul63, L ysl75 and A rg l7 6 , are also present in subsite 2 and
m ay participate in ionic interactions or w ater m ediated hydrogen bonding w ith an
ionizable am ine in an inhibitor [9]. Burnett and coworkers proposed that potent inhibitors
o f BoNT/A LC m ust interact with residues present in both binding subsites 1 and 2 in the
substrate binding region [9].
Efforts in small m olecule and peptidic BoN T type A (BoNT/A ) inhibitor
discovery have been ongoing since the late 1990’s [8"9,13,18]. Silhar and coworkers
reported that a hydroxam ate compound used in com bination w ith the non-com petitive
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natural product inhibitor chicoric acid resulted in synergistic inhibition o f BoN T/A LC
but hydroxam ate com pounds raise toxicity concerns due to prom iscuous zinc chelation
[19,2°] R ecentiy? quinolinol com pounds have received attention as inhibitors o f BoN T/A
LC [4> 17,21] in part because o f structural dissim ilarity to other know n m etalloprotease
inhibitors. M oreover, quinolinol com pounds have low m olecular weights, offer several
points for structure activity investigation and can be readily synthesized by a
m ulticom ponent condensation [17]. Caglic and coworkers screened 188 quinolinol
compounds for inhibitory activity against BoN T/A LC and found that 80 % o f the m ost
active com pounds had IC50 values below 10 pM w ith few in the sub-m icrom olar range
[17]. Structure activity relationship studies revealed that the quinolinol m oiety alone was
not sufficient to elicit any inhibitory activity against BoN T/A LC. Their analysis and
m odeling led to the hypothesis that aryl groups at R 2 and R 3 o f the tem plate (Figure 2)
prom ote proper conform ation, perm it binding into the active site and that substitutions at
positions R 2 and R 3 (Figure 2) with bulky heterocyclic groups improved inhibitory
activity [17]. However, no detailed enzym atic or kinetic studies were carried out to
investigate the m echanism by w hich quinolinols inhibit BoNT/A.

FIGURE 2: Structures o f the quinolinol scaffold (left) and compounds 4-chloro- A-[(4fluorophenyl) methyl] pyridin-3-amine (MSU58) and 4-chloro-(3-fluorophenyl) methyl
benzenesulfonamide (MSU84) (right).
4

There are three types o f inhibition (com petitive, noncom petitive, and
uncom petitive) that are used to describe how an inhibitor binds to the target enzyme.
Characterization o f the m echanism o f inhibition o f BoNT/A LC by quinolinol
com pounds can provide insights on how these com pounds interact with the target. For
exam ple, know ing w hether inhibitor and substrate binding are m utually exclusive events
and w hether an inhibitor binds in the substrate binding site or another distinct site w ould
facilitate structure activity relationship studies, the design o f m ore potent inhibitors, and
the interpretation o f inhibitory data. This understanding is particularly needed for
BoN T/A LC, a challenging target with an unusually large substrate-enzym e interface
where a small m olecule m ay need to possess m ultiple functionalities to block the binding
o f substrate. M olecular docking studies perform ed by Roxas-D uncan and coworkers with
five quinolinol analogs predicted that they interact with the zinc cation in the
hydrophobic pocket o f the LC, blocking the active site [4], Conversely, subsequent
enzyme binding studies by Lai and coworkers reported noncom petitive inhibition o f
BoN T/A LC by quinolinol com pound 7-(phenyl(8-quinolinylam ino) m ethyl)-8-quinolinol
(QAQ) [21], N oncom petitive inhibitors bind to a site distinctly different from the substrate
binding site and bind equally well to free enzym e and to enzym e-substrate complex.
Optim ization efforts o f noncom petitive inhibitors m ust focus on the site where the
inhibitor binds, distinct from the substrate binding site, and consider the structural
changes that result from substrate binding.
In this work, we determ ine the inhibition m echanism s o f two novel quinolinol
inhibitors M SU58 and M SU84 (Figure 2) against BoN T/A LC m etalloprotease activity
using a com m ercially available fluorescent resonance energy transfer (FRET) substrate,
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SNAPtide. W hile the docking studies w ith several quinolinol inhibitors suggest that these
com pounds block the active site zinc, experim ental kinetic studies on QAQ support
noncom petitive inhibition. To increase the understanding o f the m echanism o f action o f
quinolinol derivatives against BoN T/A LC, we apply the FIQ correction and determ ine
the m echanism o f inhibition by new com pounds, M SU58 and M SU84.

C H A PTER 2: M ETH ODS AND M ATERIALS

Materials
A recom binant BoNT/A LC (product #610) (residues 1- 429 o f the full length BoNT/A),
its fluorogenic substrate SNAPtide (FITC/DABCY L) (product #521) and the unquenched
peptide (product #528) were obtained from List Biological Laboratories (Cam pbell, CA).
The inhibitors, M SU58 and M SU84 were synthesized in the M ontclair State U niversity
m edicinal chem istry laboratory. All other buffers and reagents were obtained from Fisher
Scientific (Hampton, NH).

Preparation o f buffers, substrate (SNAPtide), enzyme (BoNT/A LC) and unquenched
product
Enzym e dilution buffer (50 m M K -HEPES with 0.05 % Tween 20, pH 7.4) and
assay buffer (40 m M K-HEPES 0.01 % Tw een 20, pH 7.4), w ere m ade from the free acid
form o f HEPES (H-HEPES) and potassium -H EPES (K-HEPES). Each buffer solution
was filter sterilized using a C om ing 0.22 pM filter and refrigerated. A 2.5 m M stock
solution o f SNAPtide was prepared by reconstituting 200 nm oles o f the com m ercial
product in 80% DM SO and a 2 pM stock solution o f BoNT/A LC, by reconstituting 10
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pg in enzym e dilution buffer, per m anufacturer’s instructions. The unquenched peptide
(50 nm oles) was reconstituted in DM SO to m ake a 500 pM stock solution. All the
solutions w ere stored in aliquots at -20 °C and all assays w ere conducted in 40 m M KHEPES 0.01 % Tween 20 pH 7.4 at room tem perature unless otherw ise stated.

Determination o f kinetic parameters
The kinetic param eters and standard curves w ere m easured concurrently in Costar h alf
area black 96 well plates (Costar #3694, Com ing Inc). The fluorescent signal was
m onitored in a Biotek (Synergy H I, # 15061913) plate reader set (490 nm excitation, 523
nm emission; gain (sensitivity) o f 50) for 90 m inutes at 1 m inute intervals w ith shaking
for 30 seconds betw een each read [22]. Unquenched peptide w as diluted in assay buffer to
final concentrations ranging from 0.3 pM to 3 pM to obtain a standard curve. The slope
o f the graph o f fluorescent signal versus concentration o f the unquenched peptide was
used to convert the fluorescent signals o f the assay wells to initial velocities (V0) in
pM /m in.
The V0 m easurem ents were conducted in triplicate at different substrate
concentrations, w ith m axim um substrate concentration o f 50 pM , in a 50 pL well volume
containing 4.2 nM BoN T/A LC. Diluted substrate solutions were prepared in 16 %
DM SO in assay buffer and each substrate solution contributed 1.6 % D M SO to the well.
The final concentration o f DM SO in the well was 3.2 % (1.6 % from SNAPtide and 1.6
% from inhibitor). Control experim ents dem onstrated that BoN T/A LC could tolerate
increasing DM SO concentrations up to 6 % DM SO in assay buffer with no significant
reduction in reaction rate.
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Determination o f inhibition constants (Kj) and dissociation constant (KD)
The Kj o f M SU58 and M SU84 was determ ined using concentrations o f 0, 3, 6 and
9 pM o f each inhibitor. A 10 mM stock o f inhibitor was initially diluted in DM SO and
then subsequently in assay buffer to m ake a 90 pM inhibitor solution. Serial dilutions
were made in 16 % D M SO in assay buffer and each inhibitor dilution contributed a final
DM SO concentration o f 1.6 % in a 50 pL final assay volum e containing 4.2 nM BoN T/A
LC and m ultiple SNAPtide concentrations ranging from 2.9 ¡iM to 50 pM .
The inhibitor, assay buffer and BoN T/A LC were preincubated for 30 m inutes on
a plate shaker at room tem perature after which the SNAPtide was added and placed in the
Synergy H I plate reader for a kinetic read. Controls for the assay include, BoN T/A LC
and SNAPtide in the absence o f inhibitor, SNAPtide alone, assay buffer alone and the
unquenched peptide at varying concentrations. The reciprocals o f the VQw ere plotted
against the inhibitor concentration to form Dixon plots, from which the Kj values were
estimated. The Kj values were also determ ined from the IC50 values, using the ChengPrusoff equation [23].
To determ ine the K D the fluorescence o f BoN T/A LC (0.2 pM ) in 250 pL o f 40
mM K-HEPES pH 7.4 in the presence o f varying concentrations o f M SU58 and M SU84
(0.5 pM to 23 pM ) was m onitored at 280 nm excitation and 323 nm em ission in the
fluorimeter. The fluorescent signals w ere corrected for inner filter effect using correction
factors obtained from the fluorescence o f 0.2 pM o f tryptophan in 250 pL 40 mM KHEPES pH 7.4 in the presence o f 0.5 pM to 23 pM M SU58 and M SU84. The K D was
determ ined by fitting the data in KaleidaGraph (Synergy Software, Reading, PA) to the
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equation: (-m 2 )/(l+ (m l/m 0 )) + m3; where m l= E stim ated K D; m 2=M inim um signal
value; m 3=M axim um signal value

FIQ Correction
In order to correct for the quenching effect o f cleaved D A BC Y L m olecules on the
total fluorescence o f the product, FIQ correction factors were determ ined using the
m ethods described in [24,25]. Briefly, SNAPtide dilutions w ere m ade sim ilar to that used
in the kinetic assays (2.9 pM to 50 pM ) and the unquenched peptide prepared to a final
concentration o f 0.5 pM unquenched peptide in a final volum e o f 50 pL. Fluorescent
endpoint readings o f each SNAPtide concentration in assay buffer (50 pM to 0 pM in 50
pL assay volum e, 2:3 fold dilution) and 0.5 pM o f unquenched peptide in the presence o f
each SN APtide concentration were m easured after 15 m inutes incubation at 25 °C as
described in the previous section. The endpoint reading o f 0.5 pM unquenched product
was m easured total signal o f the unquenched product in the absence o f SNAPtide. The
experim ent was perform ed in triplicate.
To calculate the correction factors, the signal o f 0.5 pM unquenched peptide in
the presence o f SN APtide was subtracted from the signal o f each representative
SNAPtide concentration to obtain the apparent signal o f the 0.5 pM unquenched peptide
in the presence o f each SNAPtide concentration. The signal o f the unquenched peptide in
the presence o f each SN APtide concentration w as divided by the total signal from the 0.5
pM unquenched peptide, to give a ratio o f how m uch signal reaches the detector in the
presence o f each SN APtide concentration. This gave the FIQ correction factor and the
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values can be found in (Table 2). The initial velocities were corrected by dividing w ith
the FIQ calculated at each substrate concentration i24\

Turbidimetric Solubility Assay
To investigate the time dependent solubility o f M SU58 and M SU84, a 1:2 fold serial
dilution o f inhibitors was m ade to obtain concentrations in the range o f 10 pM to 40 pM
in a final volum e o f 100 pL in a clear 96 well polypropylene plate. Inhibitor dilutions
were m ade w ith final a D M SO concentration o f 3.2 % to m im ic assay conditions w ith
control w ells containing 3.2 % DM SO in assay buffer. The plate was shaken for 5
m inutes on a plate shaker after w hich a tim e course absorbance reading is m easured at
600 nm at 25 °C.
The solubility o f M SU58 and M SU84 in the assay buffer was investigated using the
procedure described in [26]. Concentrations used w ere in the range 0.16 pM to 100 pM in
a final volum e o f 100 pL in a clear 96 well polypropylene plate by adding 1 pL inhibitor
to 99 pL assay buffer. Final DM SO concentration was 1 %.

Model discrimination analysis using DynaFit4 software
DynaFit4 software (BioKin Ltd, W atertown, M A) was used to determ ine the m ost
plausible inhibition m echanism . A DynaFit script specifying the fit param eters and
concentration o f the reactants was prepared for each likely inhibition model
(Com petitive, noncom petitive and uncom petitive). For each model, the catalytic activity
(&cat) was fixed to the value determ ined from the kinetic experiments. First order rate
constants (kon and k0f) and the second order rate constants in each m odel were allowed to
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vary as adjustable param eters. The experim ental data was then exported to D ynaFit and
analyzed through a non-linear least squares regression.

CH A PTER 3: RESULTS AND DISCUSSIO N
This study w as aim ed at identifying the m echanism by which the two quinolinol
com pounds (M SU58 and M SU84) inhibit BoN T/A LC and determ ining the num ber and
nature o f inhibitor binding sites present on the enzyme. The results will benefit structure
activity relationship (SAR) studies and drug optim ization efforts towards the
developm ent m ore potent BoNT/A LC inhibitors.

Steady-state kinetics o f BoNT/A LC with SNAPtide support competitive inhibition.
The kinetic param eters (K M, m axim um velocity (F max) and £cat) o f BoNT/A LC w ere
determ ined using the substrate analog SNAPtide, a FRET peptide with an FITC
fluorescent donor on the N-term inus and a D A BCYL quencher at the C-term inus.
BoN T/A LC catalyzes the cleavage o f SNAPtide, releasing the FITC from the DABCYL;
the resulting increase in fluorescence emission was m easured to m onitor product
form ation over time. The fluorescence em ission intensities were converted to V0 values
using standard curves determ ined in the same experiment. The V0 values w ere determ ined
at m ultiple SNAPtide concentrations and data w as fitted to the M ichaelis-M enten
equation using G raphPad Prism 6 software (Figure 3).
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a
[M$U58]= 0 uM
-*■ ifvtSU58]= 3 uM
— fMSU53]= 6 nM
-*■ |MSU58]=9 pM

[MSU58]= 0 uM
[MSU5SJ* 3 uM
•*" [MSU58)- 6 I 'M
[MSU58]= 9 uM

C

■+■

(MSU58]= 0 >iM
[MSU58]= 3 iiU
[MSU58}= 6 fsM
[M$U58J= 9 |iM

d
(MSU84{= 0 nM
[MSU84]= 3 uM
pMSU84}= 6 uM
[MSU84j= 9 uM

♦ [MSU84]= 0 jiM
-*• [MSU84}= 3 uM
[MSU84j= 6 fiM
[MSU84]= 9 jtM

■+■

[MSU84]= 0 uM
(IVfSU84]= 3 uM
[MSU84]= 6 UM
[MSUS4]~ 9 uM

FIGURE 3: Effect of inhibitors MSU58 and MSU84 on BoNT/A LC kinetics. BoNT/A LC
activity was measured in the presence of (•) 0 pM, (■) 3 pM, (A ) 6 pM and (▼) 9 pM MSU58
(a-c) and MSU84 (d-f) at 490/523nm in a BioteK Synergy HI plate reader. Figures of three
independent experiments with each inhibitor, conducted in 40 mM K-HEPES containing 0.01%
Tween 20 at room temperature are illustrated. The V0 values were corrected for FIQ (Results in
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data file: MSU58 data > botox assay 05.23.16.581; botox assay 05.23.16.582; botox assay
06.14.16.58.1 and MSU84 data > botox assay 04.27.16.84ii; botox assay 04.11.16.84; botox
assay 08.09.16.84)

A kcat for BoN T/A LC on SNAPtide was determ ined to be 0.21 s '1 m easured at room
tem perature in 40 m M K-HEPES pH 7.4 (Table 1); this value is in qualitative agreem ent
with the kcat o f 0.28 s '1 reported previously by Feltrup and Singh at 37 °C in 20 m M
HEPES, 0.1 % Tw een 20 pH 7.6 [24]. The KM we determ ined (46.4 ± 0.8 pM ) was
approxim ately twice that determ ined by Feltrup and Singh (~ 22 pM ); the different
ranges o f substrate concentrations used in the assays ( 1 - 5 0 pM here and 1 - 1 0 pM , by
Feltrup and coworkers, respectively) in addition to the different buffer and Tw een 20
concentrations m ay be responsible for the difference in K M values. The K M value o f 46.4
± 0.8 pM determ ined here agrees with the value o f 42.3 ± 2.4 reported by Lai and
coworkers in an excess o f zinc acetate [21]. In the presence o f 0, 3, 6 and 9 pM inhibitor
(Table 1), the V0 versus the SNAPtide concentration curves shifted to the right for both
inhibitors, indicating an increase in K M with increasing inhibitor concentration (Figure
3). Presence o f the inhibitor did not significantly affect Fmax. Linew eaker-B urk plots
(Figure 4) further show an increasing K M and unchanged Vmax with increasing inhibitor
concentrations. A decrease in the £cat/K M in the presence o f increasing inhibitor
concentration was observed for both inhibitors (Table 1). These findings are consistent
with com petitive inhibition.
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FIGURE 4: Representative Lineweaver-Burk Plots of the reciprocal of the initial velocity ( 1/V0)
min/nM versus the reciprocal of the SNAPtide concentration (1/ [SNAPtide] (pM '1)) in the
presence of varying concentrations of MSU58 (A) and MSU84 (B) (♦) = 0 pM, (■) = 3 pM, (À)
= 6 pM and (x) = 9 pM. Data was obtained at room temperature in 40 mM K-HEPES pH 7.4
containing 0.01% Tween 20. Results are representative of three independent experiments (Data
file: MSU58 data> botox assay 05.23.16.581and MSU84 data> botox assay 04.27.16.84ii). See
Appendix A3 for full description.

TABLE 1

Kinetic param eters o f the BoN T/A LC catalyzed reaction in the presence o f
M SU58 and M SU84
Km ( hM)

[1]
(HM)

MSU58

MSU84

MSU58

MSU84

0

46 ±3

45 ± 11

46 ± 1

3

47 ±3

55 ±9

44 ±4

6

99 ± 13

106 ± 18

9

104 ±8

94 ±24

Vmax (nM/min)

kcof/KM (mM-1s-1)

MSU58

(s *)
MSU84

MSU58

MSU84

58 ±9

0.18 ±0.01

0.23 ±0.04

3.8 ±0.4

5.1 ±2.1

57 ±4

0.17 ±0.02

0.23 ±0.02

3.6 ±0.7

4.2 ± 1.1

54 ±5

73 ±2

0.22 ±0.02

0.29 ±0.01

2.2 ±0.5

2.7 ±0.5

48 ±2

57 ±7

0.19 ±0.01

0.23 ±0.03

1.8 ±0.2

2.4 ±0.9

kc a t

Increasing KM and a constant Emax were observed for both inhibitors and are consistent with
competitive inhibition. &cat values were calculated from the equation Vmax/[ET], where [ET] was
the enzyme concentration in the assay (4.2 nM). Values are ± S.E for an average of three
independent experiments.
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Modified FIQ correction fo r higher SNAPtide concentrations.
It was necessary to correct the data for FIQ, which is the tendency o f the quencher on the
intact or cleaved SNAPtide to absorb some o f the light fluoresced by the FITC in another
m olecule o f a cleaved SNAPtide [24‘25]. This correction had not been reported when the
previous and only kinetic studies on inhibition m echanism o f a quinolinol com pound on
BoN T/A LC w ere conducted on QAQ. Feltrup and Singh outlined a correction using the
slope o f the FIQ correction factors versus SNAPtide concentration [24]. W e used higher
substrate concentrations than were used by Feltrup et al. At [SNAPtide] > 10 or 15 pM ,
the FIQ correction factors versus the SNAPtide concentration relationship was not linear
(Figure 5) and we w ere not able to use the slope to correct our data. Consequently, we
calculated the correction factors (Table 2) as outlined by Liu et al.[25]. The uncorrected
K m (17.8 ± 1 . 6 pM ) was 2.6-fold low er than the FIQ -corrected KM (46.4 ± 0.8 pM )
(Figure 6). The correction also resulted in a 2.3 tim es higher £cat value o f 0.21 ± 0.02 s '1
com pared to 0.09 ± 0.01 s '1 (uncorrected £cat). Feltrup and Singh reported a 1.96-fold and
2.12-fold increase in the K M and kcat respectively, as a result o f the FIQ correction, in
agreem ent w ith the results here.[24] The FIQ correction is necessary when using
SNAPtide as the substrate to study BoN T/A LC kinetics but the slope cannot be applied
when concentrations o f substrate in excess o f 20 pM are used. A previously described
FIQ correction was em ployed and found to significantly affect value o f kinetic
param eters [24"25].
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[SNAPtide] (nM)
FIGURE 5: FIQ correction factors versus SNAPtide concentration are shown. The FIQ
correction factors were calculated as described by Feltrup and Singh. The relationship is linear up
to 10 - 15 pM but not linear at concentrations > 20 pM. The experiment was performed at room
temperature using 40 mM K-HEPES at pH 7.4. (Data file: FIQ factors > FIQ factors 08.09.16).

TABLE 2: FIQ correction factors
[SNAPtide] OiM)
50.0
33.3
22.2
14.8
9.9
6.6
4.4
2.9
0.0

FIQ correction
factors
0.56 ± 0.009
0.67 ± 0.026
0.69 ± 0 .0 1 5
0.70 ± 0 .0 4 9
0.82 ± 0 .0 0 8
0.94 ± 0.044
0.92 ± 0 .0 1 7
0.93 ± 0 .0 3 3
1.0

Fluorescent Internal Quenching correction factors determined for correcting the initial velocities
at the substrate concentrations used in the assay. Calculated factors are an average of three
experiments conducted at room temperature in 40 mM K-HEPES containing 0.01% Tween 20 at
pH 7.4. (Data file: > FIQ factors > FIQ factors 08.09.16).
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FIGURE 6: The change in KM (Figure A) and kcaX(Figure B) before and after FIQ correction in
the presence of different concentrations of MSU58. FIQ correction factors were determined at
conditions similar to the assay conditions. Values are the averages of three independent
experiments with S.E. (Data file: >MSU58 data > botox assay 06.14.16.58.1)

Kj and KD ofMSU58 and MSU84 with BoNT/A LC
The IC50 values for M SU58 and M SU84 were determ ined to be 3.3 ± 0.3 pM and 5.8 ± 2
pM (±S.E, N = 14, 4) respectively, using [S] o f 0.625 pM (Figure A1 in A ppendix). A
decrease in percent inhibition at concentrations >10 pM was observed for M SU84 and
was found to be due to a tim e-dependent precipitation o f M SU84 at concentrations >10
pM (Figure A 2(b) in Appendix). The better inhibition by M SU58 com pared to M SU84
m ay be due to the 3-pyridyl substituent in M SU58. Structure activity relationship studies
by Caglic and coworkers reported that a 3-pyridyl substituent at R 2 resulted in a 60 %
m ore potent inhibitor against BoNT/A LC. Docking studies revealed a hydrogen bond
betw een the 3-pyridyl substituent and the amino group o f Arg363 [4>17]. Interaction with
Arg363 is also im portant for stabilizing the binding o f the substrate for catalysis [2],
Caglic and coworkers also suggested that a m ethyl substituent at the R 4 position o f the
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quinolinol m oiety m ay account for 85 % increased inhibitory activity; introduction o f a
m ethyl group at R4 o f M SU58 and M SU 84 could be explored in future studies [ 17].
The Kj o f each inhibitor was obtained by converting the IC50 to Kj using the
C heng-Prusoff equation (See Table 3 caption) and also by em ploying D ixon plots [23].
The K x values calculated for M SU58 and M SU84 were 3.3 ± 1.1 pM and 5.7 ± 4.6 pM ,
respectively (Table 3). As expected, Kj was sim ilar to the IC50 because the [SNAPtide]
used in the screening o f the inhibitors was «

K M [27, 28]. In the Dixon plots, the

reciprocals o f the V0 from the kinetic analysis w ere plotted against the inhibitor
concentrations (Figure 7). Data at each substrate concentration was fitted individually to
a linear equation and the negative X -axis value o f the point o f intersection o f the lines in
the upper left quadrant gave an estim ate o f the Kj. For each D ixon plot, the negative Xaxis value o f the intersection point o f all pairs o f individual lines were determ ined and the
average o f these values was used to obtain the Kj o f 3.2 ± 0.5 pM for M SU 58 and 6.2 ±
0.9 pM for M SU84. These values correspond to those determ ined using the ChengP rusoff equation (Table 3) and indicate that both com pounds inhibit BoN T/A LC
protease activity in the single digit m icrom olar range, with M SU58 having a slightly
higher inhibitory effect com pared to M SU84. It can also be seen in Figure 7 that the lines
intersect in the second quadrant above the negative X-axis, supporting com petitive
enzyme inhibition m odel for each inhibitor [29]. A K D o f 1.9 ± 0.5 pM and 7.5 ± 1.1 pM
was determ ined for M SU58 and M SU84 respectively. These values are sim ilar to the K T
o f 3.2 ± 0.5 pM for M SU58 and 6.2 ± 0.9 pM for M SU84 and agree with com petitive
inhibition. Representative K D curves for M SU58 and M SU84 are illustrated in Figure 8.
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X[S]=14.8(iM

■ fS)=33.3 |iM
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FIGURE 7: Dixon Plots of MSU58 (a-c) and MSU84 (d-f) with Kj values. Figures represent
three independent experiments with each inhibitor, performed at room temperature in 40 mM KHEPES pH 7.4, containing 0.01 % Tween 20. l/V0min/nM was plotted against the concentration
of the inhibitor for varying the SNAPtide (2.9 pM - 50.0 pM). (Data file: MSU58 data: botox
assay 05.23.16.581; botox assay 05.23.16.582; botox assay 06.14.16.58.1 and MSU84 data: botox
assay 04.27.16.84ii; botox assay 04.11.16.84; botox assay 08.09.16.84)
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T A B L E 3: The IC50 values and Kj o f M SU58 and M SU84
Inhibitor

IC50 (HM)

Ki (nM)
Dixon plot

MSU58

3.3 ±0.3 (14)

3.2 ±0.5 (3)

Cheng-Prusoff
equation
3.3 ± 1.1 (14)

MSU84

5.8 ± 2.3 (4)

6.2 ±0.9 (3)

5.7 ±4.6 (4)

The Kr was determined from Dixon plots and related to the Kj value determined from the ChengPrusoff equation using predetermined IC50 values of each compound. Cheng-Prusoff equation is
given by; IC50 = Kr (1+ [S]/KM) [23]. Values are ± S.E (N).

A

20

B

FIGURE 8: Representative KD curves for MSU58 (A) and MSU84 (B). The fluorescent
signalwas plotted against the concentration of each inhibitor and fitted to the equation: (m2)/(l+(ml/m0)) + m3 in KaleidaGraph. The experiment was conducted in 40 mM K-HEPES
pH7.4 at room temperature. Results are representative of three independent experiments (Data
file: > Kd expts > BoNT A LC 58 trial 2 12.02.16 and >BoNT A LC 84 trial 3 12.02.16).

Model Discrimination Analysis
To determ ine w hether the noncom petitive and uncom petitive inhibition m echanism s
could be reasonably ruled out for M SU58 and M SU84, m odel discrim ination analysis
was perform ed. The m odel discrim ination function in the DynaFit software uses
statistical m ethods to determ ine the m ost probable inhibition m odel am ong a set o f
m odels [30]. The Akaike inform ation criterion (AIC) was used; the m odel w ith the lowest
AIC num ber is defined as the best m odel [30]. DynaFit was used to calculate the
difference betw een the AIC num bers o f each m odel and the best m odel (AAIC) and to
determ ine the A kaike weights w(AIC) [30'31]. The m ost plausible m odel has the highest
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w(AIC) w ith 1.0 being the m axim um possible w(AIC) value [31]. Results o f m odel
discrim ination analysis in Table 4 shows w(AIC) for both M SU58 and M SU 84 to be 1.00
for the com petitive m odel o f inhibition and 0.00 for either noncom petitive or
uncom petitive inhibition, indicating that the com petitive m odel o f inhibition is the m ost
likely m echanism o f inhibition o f BoN T/A LC by either M SU58 and M SU84 and that the
other m odels m ay be ruled out. This is consistent with results from Table 1, the
Linew eaver-B urk plots (Figure 4) and the D ixon plots in Figure 7.

TABLE 4: Results o f m odel discrim ination analysis using DynaFit

(I)
Model

np

Competitive

36

0.00

0.00

0.00

0.00

0.00

0.00

Uncompetitive

35

1217.7

1002.4

1094

286.1

1304.7

542.1

Noncompetitive

36

108.8

23.2

2550.8

1665.7

1163.7

1693.4

AAIC
MSU58

Model

MSU84

np

Akaike weight (w(AIC))
MSU58

MSU84

Competitive

36

1.00

1.00

1.00

1.00

1.00

1.00

Uncompetitive

35

0.00

0.00

0.00

0.00

0.00

0.00

Noncompetitive

36

0.00

0.00

0.00

0.00

0.00

0.00

Table 4 is split into (I) and (II). The AAIC of the best model is equal to 0.00; w(AIC) for the
competitive mtaodel = 1.00 supports the finding that both MSU58 and MSU84 are competitive
inhibitors of BoNT/A LC.
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Kinetic rate constants
DynaFit was used to perform a non-linear regression analysis to determ ine the kinetic
rate constants associated with the BoN T/A LC catalyzed reaction by fitting the
experim ental data to a least squares fit o f the m echanism shown in Schem e 1 [30]. Table 5
displays the average best fit association and dissociation rate constants (£on and £off)
values and inhibitor association and dissociation rate constants (kai and kd

o f three

independent experim ents w ith com pounds M SU58 and M SU84. The constants k a {and
&d i are on the same tim escale as the catalytic activity and these com pounds do not exhibit
tim e-dependent inhibition. The kcai value was fixed to the experim entally determ ined
value 0.21 s '1. The kon and &off (Table 5) are related to the K M and kcat (KM =
k on

the calculated KM is 43.3 ± 8.2 pM ; this value is close to the value o f 46.4 ± 0.8 pM
determ ined from fitting the data to the M ichaelis-M enten equation. Table 5 also shows
average values o f the ka i and kd i? w hich are related to Kj (Kx = kdA/kai). These values
were calculated to be 6.2 ± 1.3 pM for M SU58 and 5.0 ± 1.4 pM for M SU84.

E+S

E+P

+
I

E.l
SCHEME 1: The competitive mechanistic model by which MSU58 and MSU84 inhibit BoNT/A
LC.
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T A B L E 5: DynaFit determ ined rate constants and kinetic constants
Inhibitor

kon ( p M 1 s 1)

¿offO*'1)

K m (HM)

¿a.i ( p M 1 s '1)

*d.i (s ')

M SU58

0.04 ± 0.003

2.0 ± 0 .1

55 ± 7

0.13 ± 0 .0 1

0.8 ± 0 .1

M SU84

0.06 ± 0 .01

1.7 ± 0 . 4

32 ± 12

^

(pM )

6.2 ± 1.3
0.14 ± 0 .0 2
0.7 ± 0 .1
5.0 ± 1.4
DynaFit determined rate constants and determined kinetic constants; values are averages of three
independent data ± S.E. The experimental data were fit to the model in Scheme 1 and the kcat was
fixed to 0.21 s'*. The KM and Kj values in the table were calculated from the on and off rate
constants and agree with the experimentally found values.

Time-dependent Precipitation o f MSU84
A phenom enon that was observed during the determ ination o f IC50 values for M SU58
and M SU84, was the m arkedly decrease in percent inhibition at higher concentration o f
the com pound following an expected increase in percent inhibition w ith increasing
concentration o f M SU84 (Figure 9). This effect was not observed for M SU58. To
investigate this phenom enon, a turbidim etric assay was perform ed as described under the
m ethods and m aterials section. The tim e dependence o f solubility was m onitored at A6oo
nm (absorbance) over 4 hours under assay conditions. The results, displayed in Figure
9(b), revealed that M SU84 begins to precipitate out o f solution w ith tim e at higher
concentrations (20 pM and 40 pM ). At these concentrations, the com pound m olecules
begin to cluster and aggregate, increasing the turbidity o f the solution and m ay be the
underlying reason for the observed decrease in percent inhibition at those concentrations
o f M SU84. To ensure that precipitation did not impact inhibition m echanism studies, the
concentrations o f M SU84 used in the kinetic assay w ere kept below 20 pM . The
solubility assay also revealed that M SU 84 was not soluble beyond 20 pM whereas no
solubility issues were observed for M SU58 up to 100 pM (Figure 10).
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a

b

Time (min)

FIGURE 9: Time-dependent precipitation of MSU84. Turbidity reaction monitored for (a)
MSU58 and (b) MSU84. □ = 10 pM and 0 = 40 pM. The absorbance was measured at 600 nm for
4 hours with a 3.2 % final DMSO concentration. Figures represent absorbance values at the
highest concentration (40 pM) and the concentration closest to that used in the kinetic assay (10
pM). Error bars are the Standard errors of the average of two experiments. (Data file: > Solubility
> Timecourse Turbidity assay 6.28.16)
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FIGURE 10: Solubility of MSU58 and MSU84. The solubility of MSU58 (♦) and MSU84( b ) in
the assay buffer (40 mM K-HEPES pH 7.4) at room temperature. The figure is the average of
three independent experiments with standard errors. (Data file: > Solubility > Solubility 11.30.16
plate 3)
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CONCLUSION
M any reports suggest that quinolinol based compounds block the BoN T/A LC active site
via metal chelation by the 8-hydroxy quinolinol m oiety but not previously supported by
kinetic experim ents. Conversely, noncom petitive inhibition by quinolinol com pound
QAQ was reported based on kinetic studies [21], Others have suggested that quinolinol
com pounds do not inhibit BoNT/A LC by excluding the interaction o f the zinc with
water, w hich is necessary for substrate cleavage [4]. M SU58 and M SU84 w ere found to
be com petitive inhibitors o f BoNT/A LC. W e found that it was necessary to do the FIQ
correction w hen determ ining the kinetic param eters using SNAPtide and that the non
linearity o f the relationship betw een the correction factors and SN APtide concentrations
beyond 20 pM SNAPtide requires that the FIQ factors be determ ined as suggested by Liu
et al., and as we have done here when using higher SNAPtide concentrations that are
required for full M ichaelis -M enten analysis. It w as determ ined that the phenom enon
where M SU84 gives a lower percent inhibition at the highest concentration in the
screening assay was due to the slow precipitation o f this com pound at concentrations o f
20 and 40 pM . This study is the first to report experim ental data dem onstrating
com petitive inhibition o f BoN T/A LC by a quinolinol compound. In future SA R studies
and drug optim ization efforts, the addition o f a m ethyl group to the R 4 position o f the
quinolinol m oiety in M SU58 and M SU84 m ay yield m ore potent BoN T/A LC inhibitors.
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APPEN D IX

Al: Determination o f IC$g
Inhibitor stock solutions w ere m ade in DM SO at 10 mM concentration and diluted to
m ake a 1 m M solution in DM SO for the assay. Serial dilutions o f the inhibitor (1:2 fold)
were m ade in DM SO in clear polypropylene plates and transferred to the h a lf area black
well plates to obtain concentrations in the range o f 1.6 pM to 20 pM in a final well
volum e o f 50 pL. Each assay well also contained 4.2 nM BoN T/A LC and 0.625 pM
SN APtide and a final DM SO concentration in the assay o f 2 %. Experim ents were
conducted a m inim um o f four independent experim ents in the BioTek Synergy 2 for 90
m inutes; set at 485 nm excitation and 528 nm em ission with 5 m inutes shaking betw een
reads. The percent inhibition versus com pound concentration graphs w ere used to
determ ine the IC50 values in M icrosoft Excel using the Solver function and the fourparam eter logistic equation [32] (Figure A l ) .

FIGURE A l: Representative dose-response curves for determining the IC50 of compounds
MSU58 and MSU84. The curves were fit to a four parameter logistic equation using the solver
function in Microsoft Excel [32]. The curve fitting for MSU84 was done not including the 20 pM
data point. The experiments were performed in 40 mM K-HEPES pH 7.4 at room temperature.
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A2: Lineweaver-Burk analysis supports competitive inhibition
D ouble reciprocal plots (Linew eaver-Burk plots) were created in M icrosoft Excel (Figure
4). The points o f intersection on the positive y-axis and negative x-axis represent the
reciprocals o f the Vmax (1 / Vmax) and K M (1/ K M), respectively. The point o f intersection
on the y-axis did not change in the presence o f increasing inhibitor, indicating that the

Vmax ° f

reaction was independent o f inhibitor concentration for both M SU58 and

M SU84. On the other hand, the points o f intersection on the negative X -axis change w ith
inhibitor concentration, corresponding to an increasing K M w ith an increase in the
concentration o f inhibitor. This is characteristic o f the com petitive m echanism o f
inhibition and agrees w ith the trend observed in Table 1, suggesting that both M SU58
and M SU 84 compete w ith SNAPtide for the active site o f BoN T/A LC. This agrees with
the earlier docking studies that suggested that quinolinol com pounds interact w ith the
zinc cation in the hydrophobic pocket o f the active site o f BoN T/A LC [4> 17].
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FIGURE A2: Representative DynaFit traces for the competitive inhibition model for MSU58 and
MSU84. Figures are a graph of the fluorescent signal versus the time (s) for data sets obtained
from three independent experiments.
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A3: Compound synthesis
M SU 58. A m ixture o f 4-fluorobenzaldehyde (0.11 ml, 1 m mol) and 3-am inopyridine (94
mg, 1 m m ol) was stirred in a 50 ml RBF for 30 m in before adding 5-chloro-8-quinolinol
(144 mg, 0.8 m mol). The m ixture was heated to 120 °C w hereupon the reaction becam e
hom ogenous after approxim ately 1 hour; stirring continued for another 6 hours at 120 °C.
A fter TLC indicated that the quinolinol was consumed, the flask was cooled. The
contents w ere dissolved in m inim um am ount o f m ethylene chloride and loaded on a silica
gel column. Chrom atography was perform ed using 30% ethyl acetate in hexanes. The
desired product was obtained in 56% yield and greater than 97 % purity.
'H N M R (300 M Hz, C D C b): 8 8.81-8.83 (dd, 1H), 8.46-8.50 (dd, 1H), 8.17-8.18 (d, 1H),
7.94-7.96 (dd, 1H), 7.63 (s, 1H), 7.53-7.58 (m, 1H), 7.43-7.48 (m, 2H), 7.01-7.10 (m,
3H), 6.90-6.94 (m, 1H), 6.07-6.09 (d, 1H).
M SU 84. A m ixture o f 3-fluorobenzaldéhyde (0.11 ml, 1 m mol) and benzene
sulfonam ide (157 mg, 1 m mol) was stirred in a 50 ml RBF for 30 m in and was added 5chloro-8-quinolinol (144 mg, 0.8 m m ol). The m ixture was heated to 120 °C w hereupon
the reaction becam e hom ogenous after approxim ately 1 hour; stirring continued for
another 6 hours at 120 °C. A fter TLC indicated that the quinolinol was consum ed, the
flask was cooled. The contents w ere dissolved in m inim um am ount o f m ethylene
chloride and loaded on a silica gel column. Chrom atography was perform ed using 30%
ethyl acetate in hexanes. The product w as obtained in 53% yield and greater than 96 %
purity.
'H N M R (300 M Hz, C D C b): 8 8.76-8.78 (dd, 1H), 8.40-8.44 (dd, 1H), 7.62-7.65 (m,
2H), 7.53-7.57 (dd, 1H), 7.25 (s, 1H), 7.24 (s, 1H), 7.06-7.14 (m, 3H), 6.89-7.00 (m, 2H),
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6.02-6.05 (d, 1H), 5.78-5.81 (d, 1H). Com pound M SU 58 was synthesized to greater than
97 % purity.
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